Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $46.43 Average Price Target from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned a consensus rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $46.43.

A number of research analysts recently commented on DNTH shares. TD Cowen initiated coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. Oppenheimer increased their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th.

Dianthus Therapeutics Trading Down 1.1 %

DNTH stock opened at $22.74 on Friday. The company’s 50 day moving average is $25.23 and its 200 day moving average is $26.68. The stock has a market cap of $673.04 million, a price-to-earnings ratio of -9.10 and a beta of 1.74. Dianthus Therapeutics has a 1-year low of $10.02 and a 1-year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, sell-side analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its holdings in shares of Dianthus Therapeutics by 860.5% during the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after purchasing an additional 72,509 shares during the period. Rhumbline Advisers bought a new position in Dianthus Therapeutics during the 2nd quarter valued at approximately $832,000. American Century Companies Inc. lifted its holdings in Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after buying an additional 8,473 shares during the period. WINTON GROUP Ltd bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $265,000. Finally, Great Point Partners LLC increased its stake in shares of Dianthus Therapeutics by 21.3% during the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after buying an additional 132,929 shares during the period. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.